Increasing Cumulative Cisplatin Dose Linked to Hearing Loss

This article originally appeared here.
Share this content:
Increasing Cumulative Cisplatin Dose Linked to Hearing Loss
Increasing Cumulative Cisplatin Dose Linked to Hearing Loss

FRIDAY, July 1, 2016 (HealthDay News) -- There is a significant correlation for increasing cumulative cisplatin dose with hearing loss, according to a study published online June 27 in the Journal of Clinical Oncology.

Robert D. Frisina, Ph.D., from the University of South Florida in Tampa, and colleagues conducted comprehensive audiological measures on 488 North American male germ cell tumor survivors in relation to cumulative cisplatin dose.

The researchers observed a significant correlation between increasing cumulative cisplatin dose and hearing loss at 4, 6, 8, 10, and 12 kHz; for each 100 mg/m² increase there was a 3.2-dB impairment in the age-adjusted overall hearing threshold. Compared with smaller doses, cumulative cisplatin doses >300 mg/m² correlated with greater American Speech-Language-Hearing Association-defined hearing loss severity (odds ratio, 1.59) and worse normative-matched quartiles (odds ratio, 1.33). Severe to profound hearing loss was seen for 18 percent of patients. There was a significant correlation for tinnitus (40 percent of patients) with reduced hearing at each frequency (P < 0.001). There was no correlation for noise-induced damage with cisplatin dose (P = 0.59). In age- and cisplatin dose-adjusted analyses, hypertension was significantly related to overall hearing threshold.

"Follow-up of adult-onset cancer survivors given cisplatin should include routine inquiry for hearing status and tinnitus, referral to audiologists as clinically indicated, and hypertension control," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »